Bicycle Therapeutics plc
BCYCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | Maury Raycroft | $10.00(+164%) | $3.79 | StreetInsider |
| Apr 30, 2026 | Jefferies | Maury Raycroft | $12.00(+154%) | $4.72 | TheFly |
| Apr 8, 2026 | Morgan Stanley | $12.00(+141%) | $4.98 | TheFly | |
| Mar 17, 2026 | Truist Financial | Greg Renza | $8.00(+57%) | $5.09 | StreetInsider |
| Mar 17, 2026 | Morgan Stanley | Maxwell Skor | $13.00(+153%) | $5.13 | StreetInsider |
| Nov 24, 2025 | Truist Financial | $10.00(+58%) | $6.32 | TheFly | |
| Oct 31, 2025 | JMP Securities | Reni Benjamin | $12.00(+37%) | $8.76 | TheFly |
| Oct 31, 2025 | RBC Capital | Leonid Timashev | $11.00(+26%) | $8.76 | TheFly |
| Aug 11, 2025 | RBC Capital | Leonid Timashev | $27.00(+256%) | $7.59 | TheFly |
| May 5, 2025 | Morgan Stanley | Maxwell Skor | $17.00(+88%) | $9.06 | TheFly |
| Dec 18, 2024 | JMP Securities | Reni Benjamin | $26.00(+70%) | $15.32 | TheFly |
| Oct 24, 2024 | Oppenheimer | Jay Olson | $48.00(+90%) | $25.32 | StreetInsider |
| Oct 24, 2024 | B.Riley Financial | Kalpit Patel | $28.00(+11%) | $25.32 | StreetInsider |
| Sep 16, 2024 | H.C. Wainwright | Swayampakula Ramakanth | $55.00(+104%) | $27.02 | StreetInsider |
| Oct 7, 2021 | Piper Sandler | Edward Tenthoff | $76.00(+56%) | $48.69 | TheFly |
| Oct 7, 2021 | Roth Capital | Anthony Butler | $65.00(+33%) | $48.69 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Needham | maintain | Buy | Jul 30, 2026 |
| Morgan Stanley | maintain | Equal Weight | Apr 8, 2026 |
| Oppenheimer | maintain | Outperform | Mar 18, 2026 |
| Needham | maintain | Buy | Mar 18, 2026 |
| Citizens | maintain | Market Outperform | Mar 18, 2026 |
| RBC Capital | maintain | Sector Perform | Mar 18, 2026 |
| RBC Capital | downgrade | Outperform →Sector Perform | Oct 31, 2025 |
| Citizens | maintain | Market Outperform | Oct 31, 2025 |
| Morgan Stanley | maintain | Equal Weight | Aug 12, 2025 |
| JMP Securities | maintain | Market Outperform | Aug 12, 2025 |
| Oppenheimer | maintain | Outperform | Aug 11, 2025 |
| RBC Capital | maintain | Outperform | Jul 17, 2025 |
| Morgan Stanley | maintain | Equal Weight | May 6, 2025 |
| JMP Securities | maintain | Market Outperform | May 2, 2025 |
| Needham | maintain | Buy | May 2, 2025 |
| RBC Capital | maintain | Outperform | May 2, 2025 |
| B. Riley Securities | maintain | Neutral | May 2, 2025 |
| Barclays | maintain | Overweight | May 1, 2025 |
| Needham | maintain | Buy | Apr 29, 2025 |
| Needham | maintain | Buy | Apr 9, 2025 |
| Needham | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 26, 2025 |
| Citizens Capital Markets | maintain | Market Outperform | Feb 26, 2025 |
| Needham | maintain | Buy | Feb 26, 2025 |
| Stephens & Co. | maintain | Equal Weight | Jan 22, 2025 |
Earnings History
Next report: Mar 2, 2027 · EPS est. $-0.44| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $-0.15 | $-0.30 | $34.1M | $12.2M |
| Jul 30, 2026 | $-0.72 | $-0.56 | $629.0K | $4.2M |
| Apr 30, 2026 | $-0.87 | $-0.52 | $887.0K | $7.5M |
| Mar 17, 2026 | $-0.29 | $-0.94 | $48.0M | $7.0M |
| Oct 30, 2025 | $-0.85 | $-1.09 | $11.7M | $7.1M |
| Aug 8, 2025 | $-1.14 | $-0.95 | $2.9M | $8.4M |
| May 1, 2025 | $-0.88 | $-0.86 | $10.0M | $9.2M |
| Feb 25, 2025 | $-0.80 | $-0.85 | $3.7M | $7.3M |
News
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate updates. “We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2.
Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent
Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 86.2% of Bicycle